Trial Profile
A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-Manifest Huntington's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Biomarker
- Acronyms PREQUEL
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
- 20 Jun 2013 Status changed from active, no longer recruiting to completed.